In the second major pharmaceutical deal of the year, Eli Lilly will pay about $8 billion for Loxo Oncology.
The $74 billion deal could create the fourth-largest U.S. pharma firm, with a portfolio that includes nine blockbuster drugs.
Drugs such as the diabetes treatment Trulicity "led the company to a strong quarter of volume-driven revenue growth."
The deal would create the world's largest agricultural supplier but Bayer shareholders fear it will be detrimental to its pharmaceutical business
After a relentless pursuit, pharmaceutical firm Mylan pays a large premium to acquire a company that sells over-the-counter drugs.
The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.
